Plasminogen activator inhibitor-1 and vitronectin expression level and stoichiometry regulate vascular smooth muscle cell migration through physiological collagen matrices

Journal of Thrombosis and Haemostasis

Volumn 8, Issue 8, 2010, Pages 1847-1854

  Garg, N ^a   Goyal, N ^a   Strawn, T L ^a   Wu, J ^a   Mann, K M ^b   Lawrence, D A ^b   Fay, W P ^a  

^a University of Missouri   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Collagen; PAI 1; Vascular smooth muscle cell; Vitronectin

Indexed keywords

COLLAGEN; LOW DENSITY LIPOPROTEIN RECEPTOR; MUTANT PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; VITRONECTIN;

ANIMAL CELL; ARTICLE; CELL MIGRATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; EXTRACELLULAR MATRIX; MIGRATION INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; SMOOTH MUSCLE FIBER; STOICHIOMETRY; VASCULAR SMOOTH MUSCLE; WILD TYPE;

ANIMALS; AORTA; CELL MOVEMENT; COLLAGEN; GELS; GENE EXPRESSION REGULATION; HUMANS; LDL-RECEPTOR RELATED PROTEIN 1; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUSCLE, SMOOTH; MUSCLE, SMOOTH, VASCULAR; PLASMINOGEN ACTIVATOR INHIBITOR 1; VITRONECTIN;

EID: 77958610689     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2010.03907.x     Document Type: Article

References (41)

1. Carmeliet P, Collen D. Evaluation of the plasminogen/plasmin system in transgenic mice. Fibrinolysis 1994, 8:269-76.
2. Fay WP, Garg N, Sunkar M. Vascular functions of the plasminogen activation system. Arterioscler Thromb Vasc Biol 2007, 27:1231-7.
3. Loskutoff DJ, Sawdey M, Mimuro J. Type 1 plasminogen activator inhibitor. Prog Hemost Thromb 1989, 9:87-115.
4. Pandolfi A, Cetrullo D, Polishuck R, Alberta MM, Calafiore A, Pellegrini G, Vitacolonna E, Capani F, Consoli A. Plasminogen activator inhibitor type 1 is increased in the arterial wall of type II diabetic subjects. Arterioscler Thromb Vasc Biol 2001, 21:1378-82.
5. Schneiderman J, Sawdey MS, Keeton MR, Bordin GM, Bernstein EF, Dilley RB, Loskutoff DJ. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci U S A 1992, 89:6998-7002.
6. Brown SL, Lundgren CH, Nordt T, Fujii S. Stimulation of migration of human aortic smooth muscle cells by vitronectin: implications for atherosclerosis. Cardiovasc Res 1994, 28:1815-20.
7. Preissner K. Structure and biological role of Vitronectin. Annu Rev Cell Biol 1991, 7:275-310.
8. Stefansson S, Lawrence DA. The serpin PAI-1 inhibits cell migration by blocking integrin alpha-V beta-3 binding to vitronectin. Nature 1996, 383:441-3.
9. Deng G, Curriden SA, Hu G, Czekay R-P, Loskutoff DJ. Plasminogen activator inhibitor-1 regulates cell adhesion by binding to the somatomedin B domain of vitronectin. J Cell Physiol 2001, 189:23-33.
10. Degryse B, Neels JG, Czekay RP, Aertgeerts K, Kamikubo Y, Loskutoff DJ. The low density lipoprotein receptor-related protein is a motogenic receptor for plasminogen activator inhibitor-1. J Biol Chem 2004, 279:22595-604.
11. Stefansson S, Muhammad S, Cheng X-F, Battey F, Strickland DK, Lawrence DA. Plasminogen activator inhibitor-1 contains a cryptic high affinity binding site for the low density lipoprotein receptor-related protein. J Biol Chem 1998, 273:6358-66.
12. Kamikubo Y, Neels JG, Degryse B. Vitronectin inhibits plasminogen activator inhibitor-1-induced signalling and chemotaxis by blocking plasminogen activator inhibitor-1 binding to the low-density lipoprotein receptor-related protein. Int J Biochem Cell Biol 2009, 41:578-85.
13. Li S, Lao J, Chen BPC, Li Y, Zhao Y, Chu J, Chen KD, Tsou TC, Peck K, Chien S. Genomic analysis of smooth muscle cells in three-dimensional collagen matrix. FASEB J 2003, 17:97-9.
14. Stegemann JP, Nerem RM. Altered response of vascular smooth muscle cells to exogenous biochemical stimulation in two- and three-dimensional culture. Exp Cell Res 2003, 283:146-55.
15. Dufourcq P, Louis H, Moreau C, Daret D, Boisseau MR, Lamazière JMD, Bonnet J. Vitronectin expression and interaction with receptors in smooth muscle cells from human atheromatous plaque. Arterioscler Thromb Vasc Biol 1998, 18:168-76.
16. Stefansson S, Petitclerc E, Wong MKK, McMahon GA, Brooks PC, Lawrence DA. Inhibition of angiogenesis in vivo by plasminogen activator inhibitor-1. J Biol Chem 2001, 276:8135-41.
17. Berkenpas MB, Lawrence DA, Ginsburg D. Molecular evolution of plasminogen activator inhibitor-1 functional stability. EMBO J 1995, 14:2969-77.
18. Li SH, Gorlatova NV, Lawrence DA, Schwartz BS. Structural differences between active forms of plasminogen activator inhibitor type 1 revealed by conformationally-sensitive ligands. J Biol Chem 2008, 283:18147-57.
19. Cao C, Lawrence DA, Li Y, von Arnim CA, Herz J, Su EJ, Makarova A, Hyman BT, Strickland DK, Zhang L. Endocytic receptor LRP together with tPA and PAI-1 coordinates Mac-1-dependent macrophage migration. EMBO J 2006, 25:1860-70.
20. Carmeliet P, Kieckens L, Schoonjans L, Ream B, Nuffelen A, Prendergast G, Cole M, Bronson R, Collen D, Mulligan R. Plasminogen activator inhibitor-1 gene deficient mice. I. Generation by homologous recombination and characterization. J Clin Invest 1993, 92:2746-55.
21. Zheng X, Saunders T, Camper S, Samuelson L, Ginsburg D. Vitronectin is not essential for normal mammalian development and fertility. Proc Natl Acad Sci U S A 1995, 92:12426-30.
22. Eitzman DT, McCoy RD, Zheng X, Fay WP, Shen T, Ginsburg D, Simon RH. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest 1996, 97:232-7.
23. Ray JL, Leach R, Herbert J-M, Benson M. Isolation of vascular smooth muscle cells from a single murine aorta. Methods Cell Sci 2002, 23:185-8.
24. Poon M, Marx SO, Gallo R, Badimon JJ, Taubman MB, Marks AR. Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest 1996, 98:2277-83.
25. Hotary K, Allen E, Punturieri A, Yana I, Weiss SJ. Regulation of cell invasion and morphogenesis in a three-dimensional type I collagen matrix by membrane-type matrix metalloproteinases 1, 2, and 3. J Cell Biol 2000, 149:1309-23.
26. Kim TJ, Kim JH, Jin YR, Yun YP. The inhibitory effect and mechanism of luteolin 7-glucoside on rat aortic vascular smooth muscle cell proliferation. Arch Pharm Res 2006, 29:67-72.
27. Wu J, Stevenson MJ, Brown JM, Grunz EA, Strawn TL, Fay WP. C-reactive protein enhances tissue factor expression by vascular smooth muscle cells: mechanisms and in vivo significance. Arterioscler Thromb Vasc Biol 2008, 28:698-704.
28. Izumi M, Shimo-Oka T, Morishita N, Ii I, Hayashi I. Identification of the collagen-binding domain of vitronectin using monoclonal antibodies. Cell Struct Funct 1988, 13:217-25.
29. Dufourcq P, Couffinhal T, Alzieu P, Daret D, Moreau C, Duplaa C, Bonnet J. Vitronectin is up-regulated after vascular injury and vitronectin blockage prevents neointima formation. Cardiovasc Res 2002, 53:952-62.
30. Wagenseil JE, Mecham RP. Vascular extracellular matrix and arterial mechanics. Physiol Rev 2009, 89:957-89.
31. Voss B, Rauterberg J. Localization of collagen types I, III, IV and V, fibronectin and laminin in human arteries by the indirect immunofluorescence method. Pathol Res Pract 1986, 181:568-75.
32. Blasi F. uPA, uPAR, PAI-1: key intersection of proteolytic, adhesive and chemotactic highways? Immunol Today 1997, 18:415-7.
33. Czekay R-P, Aertgeerts K, Curriden SA, Loskutoff DJ. Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. J Cell Biol 2003, 160:781-91.
34. Otsuka G, Agah R, Frutkin AD, Wight TN, Dichek DA. Transforming growth factor beta-1 induces neointima formation through plasminogen activator inhibitor-1-dependent pathways. Arterioscler Thromb Vasc Biol 2006, 26:737-43.
35. Mimuro J, Loskutoff DJ. Purification of a protein from bovine plasma that binds to type 1 plasminogen activator inhibitor and prevents its interaction with extracellular matrix. J Biol Chem 1989, 264:936-9.
36. Peng L, Bhatia N, Parker AC, Zhu Y, Fay WP. Endogenous vitronectin and plasminogen activator inhibitor-1 promote neointima formation in murine carotid arteries. Arterioscler Thromb Vasc Biol 2002, 22:934-9.
37. Ploplis VA, Cornelissen I, Sandoval-Cooper MJ, Weeks L, Noria FA, Castellino FJ. Remodeling of the vessel wall after copper-induced injury is highly attenuated in mice with a total deficiency of plasminogen activator inhibitor-1. Am J Pathol 2001, 158:107-17.
38. Carmeliet P, Moons L, Lijnen HR, Janssens S, Lupu F, Collen D, Gerard RD. Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation - A gene targeting and gene transfer study in mice. Circulation 1997, 96:3180-91.
39. de Waard V, Arkenbout EK, Carmeliet P, Lindner V, Pannekoek H. Plasminogen activator inhibitor 1 and vitronectin protect against stenosis in a murine carotid artery ligation model. Arterioscler Thromb Vasc Biol 2002, 22:1978-83.
40. Lijnen HR, van Hoef B, Umans K, Collen D. Neointima formation and thrombosis after vascular injury in transgenic mice overexpressing plasminogen activator inhibitor-1 (PAI-1). J Thromb Haemost 2004, 2:16-22.
41. Stefansson S, Haudenschild CC, Lawrence DA. Beyond fibrinolysis: the role of plasminogen activator inhibitor-1 and vitronectin in vascular wound healing. Trends Cardiovasc Med 1998, 8:175-80.